CTI BioPharma Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	-1.57	-2.28	-2.83	-4.27	-4.88	Upgrade
Depreciation & Amortization	-	0.02	0.02	0.02	0.02	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-0	0.01	Upgrade
Asset Writedown & Restructuring Costs	-	0.09	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-	-	-	-	0.46	Upgrade
Stock-Based Compensation	-	-	0.2	2.42	1.61	Upgrade
Other Operating Activities	-0.16	-0.01	0	-	-	Upgrade
Change in Accounts Receivable	-	-	-	0.08	-0.16	Upgrade
Change in Accounts Payable	0.05	-0.08	-0.02	-0.12	0.11	Upgrade
Change in Other Net Operating Assets	-0.06	0.34	-0.09	-0.22	-0.08	Upgrade
Operating Cash Flow	-1.73	-1.93	-2.74	-2.1	-2.91	Upgrade
Investment in Securities	-	-	-	-	0.04	Upgrade
Investing Cash Flow	-	-	-	-	0.04	Upgrade
Issuance of Common Stock	2.48	0.84	2.55	0.05	7.9	Upgrade
Other Financing Activities	-0.08	-0.04	-	-	-	Upgrade
Financing Cash Flow	2.4	0.8	2.55	0.05	7.9	Upgrade
Miscellaneous Cash Flow Adjustments	-0	-	-	-	-	Upgrade
Net Cash Flow	0.67	-1.13	-0.19	-2.05	5.03	Upgrade
Levered Free Cash Flow	-1.24	-0.95	-1.67	-0.49	-1.26	Upgrade
Unlevered Free Cash Flow	-1.24	-0.95	-1.67	-0.49	-1.26	Upgrade
Change in Net Working Capital	0.16	-0.41	0.12	0.25	0.13	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.